Quantcast

Industry news that matters to you.  Learn more

Immunovia, OHSU Collaborating on Early Detection Test for Pancreatic Cancer

Immunovia AB and the Knight Cancer Institute at Oregon Health & Science University (OHSU) formed a collaboration to confirm, validate and commercialize a blood test for the early diagnosis of pancreatic cancer. The test called IMMray™ PanCan-d analyses a patient’s immune system for early signs of disease. The collaboration will also enable researchers to explore biomarkers for a number of other cancer types.

C2N Diagnostics Expands Partnership with Washington University School of Medicine to Commercialize a Clinical Blood Test for Detection of Early Alzheimer’s Disease

C2N Diagnostics, LLC (C2N) recently announced that it has expanded its partnership with Washington University School of Medicine (WUSM) in St. Louis. The objective of this collaboration is to commercialize a clinical blood test for detecting the earliest stages of Alzheimer’s disease (AD) as well as mild cognitive impairment (MCI). Under terms of the agreement, C2N has acquired the exclusive worldwide commercial license rights to a suite of technologies developed in the laboratories of Professors Randall Bateman, MD and David Holtzman, MD, in the Department of Neurology at WUSM.

AbsoluteIDQ p180 by Biocrates Life Sciences AG: Cutting-edge Test kit Made in Austria Helps Develop the World’s First Metabolomics-based Blood Test to Predict Alzheimer’s Disease

A US research team has developed the world’s first blood test capable of predicting, with 90% accuracy, the risk of Alzheimer’s disease 2-3 years in advance. The findings, published in Nature Medicine, were generated using the AbsoluteIDQ p180 test kit by Austrian Biocrates Life Sciences AG.

VolitionRx Finds Simple Blood Test Detects 85% of Colorectal Cancers and Over 50% of Polyps

VolitionRx Limited (VNRX:OB), a life sciences company focused on developing blood-based diagnostic tests for different types of cancer, recently released new data showing that when combining two of its proprietary NuQ® assays into one test, they can achieve 85% detection rates at 85% specificity for colorectal cancer. The data also shows that Volition’s two-assay test can detect more than 50% of precancerous polyps. These new findings come from its ongoing prospective study with CHU Dinant Godinne | UCL Namur Hospital in Belgium.

The Michael J. Fox Foundation Funds Research to Develop Parkinson’s Blood Test

Research being performed by Durin Technologies, Inc., exploring the development of a novel blood test for Parkinson’s disease was recently awarded a second grant from The Michael J. Fox Foundation for Parkinson’s Research.